Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Data Call Technologies, Inc. (OTC: DCLT).

Full DD Report for DCLT

You must become a subscriber to view this report.



About Data Call Technologies, Inc. (OTC: DCLT)

Logo for Data Call Technologies, Inc. (OTC: DCLT)

Since inception in , Data Call s continued mission is to exponentially grow it s offering of it s proprietary subscription services by integrating cutting edge information/content delivery solutions to and within the control of retail and commercial re sellers and end users. The Company s services put its clients in control of real time news and other dynamic content, displayed within one or multiple locations, spanning from local, regional and global end points, through Digital Signage and Kiosk networks. Our business plan continues to focus on growing our client base by effectively offering real time information/content displayed through Digital Signage and Kiosk networks, seeking to improve the delivery, security, and variety of information/content services to the growing Digital Signage and Kiosk community.

 

 

 

Current Management

  • Timothy Vance / CEO, President, COO
  • Gary Woerz / CFO
    • Gary D. Woerz, age , Chief Financial Officer and Director Mr. Woerz was appointed as CFO and a director of Data Call Tech in January . From March to January , Gary Woerz provided financial consulting services to private and public companies. From September to January , Mr. Woerz was CFO and COO of Larrea Biosciences, a public company. From July to July , Mr. Woerz was the CFO of Virexx Medical Corp., a public company organized under the laws of the Province of Alberta, Canada. From April to May , Mr. Woerz served as CFO of American International Industries, Inc., a public reporting company.
  • John Shafer /
    • John Schafer, age , Director Mr. Schafer has been a member of Data Call s Board of Directors since his appointment in May . From March through the present, Mr. Schafer has served as Vice President of Operations of Waterfront Ventures LLC, a private company engaged in real estate development and operations, specializing in the hospitality and public service industry. Mr. Schafer s duties at Waterfront Ventures include strategic and financial planning and chief of operations. In addition, from through the present, Mr. Schafer has been President and principal of JLS Holdings LLC, a private company engaged in the business of marketing, business development, financial planning and promotion, primarily for the real estate and hospitality industry, among others.
  • Timothy Vance /
  • Gary Woerz /
    • Gary D. Woerz, age , Chief Financial Officer and Director Mr. Woerz was appointed as CFO and a director of Data Call Tech in January . From March to January , Gary Woerz provided financial consulting services to private and public companies. From September to January , Mr. Woerz was CFO and COO of Larrea Biosciences, a public company. From July to July , Mr. Woerz was the CFO of Virexx Medical Corp., a public company organized under the laws of the Province of Alberta, Canada. From April to May , Mr. Woerz served as CFO of American International Industries, Inc., a public reporting company.

Current Share Structure

  • Market Cap: $858,357 - 03/09/2018
  • Authorized: 200,000,000 - 03/09/2018
  • Issue and Outstanding: 145,484,165 - 03/09/2018
  • Float: 94,188,016 - 09/30/2017

 


Recent Filings from (OTC: DCLT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 11 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 09 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 11 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 15 2017
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: June, 15 2017
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: June, 15 2017
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: June, 15 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 12 2017
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 08 2017

 

 


Daily Technical Chart for (OTC: DCLT)

Daily Technical Chart for (OTC: DCLT)


Stay tuned for daily updates and more on (OTC: DCLT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: DCLT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DCLT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of DCLT and does not buy, sell, or trade any shares of DCLT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/